Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia

BMC Cancer

Table 2 Patients heterozygous for the MC4R Val103Ile polymorphism, grouped according to tumour type; presence or absence of cachexia is shown

Type of cancer	Heterozygotes for the 103Ile-allele	cachectic	I/II^1,2 or related stages	III/IV^1,2 or related stages	No data about stage	n female	n male
Lymphoma	9	0	5	4	0	3	6
Colorectal	7	0	1	6	0	2	5
Leukaemia	2	0	*	*	*	0	2
Other gastrointestinal	1	0	0	1	0	0	1
Lung	1	0	1	0	0	0	1
Breast	2	0	2	0	0	2	0
Leukaemia-early stages	2	100%	*	*	*	1	1
Prostate	0	0	*	*	*	0	0
Others	1 (PNET⁵)	0	*	*	*	0	1
Total	25	8%	*	*	*	8	17

¹Lymphoma subgroups according to WHO (2001) and Ann Arbor classifications.
+The 24 patients with CLL (classification of Binet) and the 44 patients with multiple myeloma (classification of Durie and Salmon) were excluded.
²UICC classification was used for colorectal and other gastrointestinal tumors, breast and lung cancer.
³The different classifications for leucaemia and the leukaemia-early stages could not be used for these groups.
⁴Patients with myelodysplastic syndromes (MDS) or myeloproliferative syndromes (MPD).
⁵PNET: Primitive Neuroectodermal Tumour
*The classifications for these different tumour types could not be used for subgrouping.

ISSN: 1471-2407